title: Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
abstract: OBJECTIVE
  Oral anticoagulation with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) is effective but has significant limitations. AZD0837, a new oral anticoagulant, is a prodrug converted to a selective and reversible direct thrombin inhibitor (AR-H067637). We report from a Phase II randomized, dose-guiding study (NCT00684307) to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of extended-release AZD0837 in patients with AF.
  
  
  RESULTS
  Atrial fibrillation patients (n = 955) with > or =1 additional risk factor for stroke were randomized to receive AZD0837 (150, 300, or 450 mg once daily or 200 mg twice daily) or VKA (international normalized ratio 2-3, target 2.5) for 3-9 months. Approximately 30% of patients were naïve to VKA treatment. Total bleeding events were similar or lower in all AZD0837 groups (5.3-14.7%, mean exposure 138-145 days) vs. VKA (14.5%, mean exposure 161 days), with fewer clinically relevant bleeding events on AZD0837 150 and 300 mg once daily. Adverse events were similar between treatment groups; with AZD0837, the most common were gastrointestinal disorders (e.g. diarrhoea, flatulence, or nausea). d-Dimer, used as a biomarker of thrombogenesis, decreased in all groups in VKA-naïve subjects with treatment, whereas in VKA pre-treated patients, d-dimer levels started low and remained low in all groups. As expected, only a few strokes or systemic embolic events occurred. In the AZD0837 groups, mean S-creatinine increased by approximately 10% from baseline and returned to baseline following treatment cessation. The frequency of serum alanine aminotransferase > or =3x upper limit of normal was similar for AZD0837 and VKA.
  
  
  CONCLUSIONS
  AZD0837 was generally well tolerated at all doses tested. AZD0837 treatment at an exposure corresponding to the 300 mg od dose in this study provides similar suppression of thrombogenesis at a potentially lower bleeding risk compared with dose-adjusted VKA. This study is registered with ClinicalTrials.gov, number NCT00684307.
authors.affiliation: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham B18 7QH, UK. g.y.h.lip@bham.ac.uk
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
authors.forename: Lars H
authors.initials: LH
authors.lastname: Rasmussen
authors.forename: S Bertil
authors.initials: SB
authors.lastname: Olsson
authors.forename: Eva C
authors.initials: EC
authors.lastname: Jensen
authors.forename: Anders L
authors.initials: AL
authors.lastname: Persson
authors.forename: Ulf
authors.initials: U
authors.lastname: Eriksson
authors.forename: Karin F C
authors.initials: KF
authors.lastname: Wåhlander
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D015415:Biomarkers / Q000378:metabolism; D001760:Bleeding Time; D004617:Embolism / Q000517:prevention & control*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000517:prevention & control*; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000378:metabolism; D014812:Vitamin K / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D014812:Vitamin K; D013917:Thrombin
references.citation: Thromb Haemost. 2010 Mar;103(3):604-12
references.pmid: 20076850
references.citation: N Engl J Med. 2003 Sep 11;349(11):1019-26
references.pmid: 12968085
references.citation: Intern Med J. 2004 Nov;34(11):639-41
references.pmid: 15546458
references.citation: Lancet. 2006 Jun 10;367(9526):1903-12
references.pmid: 16765759
references.citation: Cardiology. 2004;102(2):115-8
references.pmid: 15133314
references.citation: Chest. 2004 Sep;126(3 Suppl):204S-233S
references.pmid: 15383473
references.citation: Cerebrovasc Dis. 2006;21(4):279-93
references.pmid: 16449807
references.citation: Circulation. 2008 Nov 11;118(20):2029-37
references.pmid: 18955670
references.citation: Am J Cardiol. 2007 Nov 1;100(9):1419-26
references.pmid: 17950801
references.citation: Stroke. 2000 Apr;31(4):828-33
references.pmid: 10753983
references.citation: Am J Kidney Dis. 2001 Jan;37(1):79-83
references.pmid: 11136171
references.citation: Europace. 2007 Nov;9(11):1006-23
references.pmid: 17897925
references.citation: Eur Heart J. 2007 Sep;28(18):2217-22
references.pmid: 17716991
references.citation: Thromb Haemost. 2009 Jun;101(6):1051-9
references.pmid: 19492147
references.citation: Drug Saf. 2005;28(4):351-70
references.pmid: 15783243
references.citation: Circulation. 2007 Jul 24;116(4):449-55
references.pmid: 17646595
references.citation: Lancet Neurol. 2007 Nov;6(11):981-93
references.pmid: 17945152
references.citation: J Am Coll Cardiol. 2002 Aug 7;40(3):484-90
references.pmid: 12142115
references.citation: Drugs Today (Barc). 2006 Jan;42(1):3-19
references.pmid: 16511607
references.citation: Heart Rhythm. 2008 Oct;5(10):1365-72
references.pmid: 18929320
references.citation: Curr Med Res Opin. 2008 May;24(5):1455-8
references.pmid: 18402716
references.citation: Eur Heart J. 2006 Aug;27(16):1979-2030
references.pmid: 16885201